Starting eculizumab as rescue therapy in refractory myasthenic crisis.
Claudia VinciguerraLiliana BevilacquaAntonella TorielloAniello IovinoGiuseppe PiscosquitoGiuseppe CalicchioPaolo BaronePublished in: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2023)
Eculizumab, a humanized monoclonal antibody that inhibits complement activation, is now approved as treatment for refractory generalized myasthenia gravis with anti-AChR antibodies. The use of eculizumab in myasthenic crisis is still investigational, but this case report suggests that it may be a promising treatment option for patients with severe clinical condition. Ongoing clinical trials will be needed to further evaluate the safety and efficacy of eculizumab in myasthenic crisis.